DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: vorinostat

Summary for Generic Name: vorinostat

Tradenames:1
Patents:10
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details

Pharmacology for Ingredient: vorinostat

Clinical Trials for: vorinostat

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Status: Not yet recruiting Condition: Mantle Cell Lymphoma

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Status: Completed Condition: Multiple Myeloma

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
Status: Active, not recruiting Condition: Unspecified Adult Solid Tumor, Protocol Specific

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Status: Terminated Condition: Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Status: Recruiting Condition: Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx

Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
Status: Active, not recruiting Condition: Multiple Myeloma

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Status: Active, not recruiting Condition: Brain Metastases

Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
Status: Terminated Condition: Malignant Solid Tumour

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
Status: Active, not recruiting Condition: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor

Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Terminated Condition: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991Oct 6, 2006RXYes7,399,787<disabled>TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991Oct 6, 2006RXYes7,732,490<disabled>TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991Oct 6, 2006RXYes7,851,509<disabled>YTREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991Oct 6, 2006RXYes8,067,472<disabled>TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc